This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Hawser, S. P.
Right arrow Articles by Paterson, D. L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hawser, S. P.
Right arrow Articles by Paterson, D. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2009, p. 3280-3284, Vol. 53, No. 8
0066-4804/09/$08.00+0     doi:10.1128/AAC.00426-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Emergence of High Levels of Extended-Spectrum-β-Lactamase-Producing Gram-Negative Bacilli in the Asia-Pacific Region: Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007{triangledown}

Stephen P. Hawser,1* Samuel K. Bouchillon,2 Daryl J. Hoban,2 Robert E. Badal,2 Po-Ren Hsueh,3 and David L. Paterson4

IHMA, 1066 Epalinges, Switzerland,1 International Health Management Associates, Inc., Schaumburg, Illinois 60173-3817,2 Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan,3 University of Queensland, Brisbane, Australia4

Received 30 March 2009/ Returned for modification 29 April 2009/ Accepted 30 May 2009

Of 3,004 gram-negative bacilli collected from intra-abdominal infections in the Asia-Pacific region during 2007, 42.2% and 35.8% of Escherichia coli and Klebsiella spp., respectively, were extended-spectrum β-lactamase (ESBL) positive. Moreover ESBL rates in India for E. coli, Klebsiella pneumoniae, and Klebsiella oxytoca were 79.0%, 69.4%, and 100%, respectively. ESBL-positive E. coli rates were also relatively high in China (55.0%) and Thailand (50.8%). Ertapenem and imipenem were the most active drugs tested, inhibiting over 90% of all species, including ESBL-positive isolates with the exception of Pseudomonas aeruginosa isolates (<90% susceptible to all study drugs) and ESBL-positive Klebsiella pneumoniae isolates (<90% susceptible to all study drugs except imipenem). Quinolones achieved 90% inhibition levels only against ESBL-negative K. pneumoniae and ESBL-negative K. oxytoca. A decline in ampicillin-sulbactam activity was noted, with only 34.5% of all Enterobacteriaceae inhibited in this study.

* Corresponding author. Mailing address: International Health Management Associates Europe Sàrl, 4 Route de la Corniche, 1066 Epalinges, Switzerland. Phone and fax: 41216519030. E-mail: shawser{at}ihmainc.com

{triangledown} Published ahead of print on 8 June 2009.

Antimicrobial Agents and Chemotherapy, August 2009, p. 3280-3284, Vol. 53, No. 8
0066-4804/09/$08.00+0     doi:10.1128/AAC.00426-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»